The global total of 49 new molecular entities (NME) and biological drugs approved and marketed for the first time. In addition, worldwide, has been listed drugs has 29 major product line extension was approved for the first time, including new indications, new formulations or new Compound; 21 new molecular entities in the world's first approved, but not yet listed.
Although these figures show that runs the pharmaceutical and biotechnology industries as a whole is good, but compared to last year's global listing of 59 new drugs, the number decreased. However, far more important to the quality of quantity, 2015 listing of new drugs, there are some very distinguished members.
Most new cancer drugs for decades
For cancer patients, this is worth celebrating, since 2015 listed over the past decade the number of new cancer drugs most of the year. Overall, the global total of 14 new cancer drugs to market for the first time.
Wherein the multiple myeloma is the most obvious area. In 2015, there are four new drug approved for multiple myeloma and listed. Prior to this, there have been ten years no new drugs for multiple myeloma, and several on the market only a handful of drugs. Chairman of the Multiple Myeloma Research Foundation borrow Walter Capone's words, in 2015, for the United States 90,000 this rare blood cancer patients, is a "watershed."
没有评论:
发表评论